#625: Does Changing the Microbiome Actually Improve Health? – Prof. Harry Sokol
Sigma Nutrition Radio
October 27, 2026
Claims about "improving the gut microbiome" are widespread, but what would improvement actually mean? How do we establish which microbial changes contribute to disease, and which simply reflect it?
Speakers Danny Lennon, Harry Sokol
TopicsNutritionHealth & Fitness
Danny Lennon (0:00)
Hello, and welcome to Sigma Nutrition Radio. This is episode 625 of the podcast. My name is Danny Lennon, and you are very welcome to the show.
Today, we're going to be talking about a range of topics that relate to the gut microbiome and health, and specifically taking a look at some of the common narratives we hear in this area, seeing, is there evidence behind them? And then based on the evidence, how we should assess that, what types of outcomes are actually meaningful that we can draw conclusions from? Where does that leave us? And then some of the new avenues in this field that might be more promising if we can get the quality of evidence that we are looking for. And so to go through all this, I'm going to be talking with Professor Harry Sokol, who is a professor of gastroenterology at San Antoine Hospital in Sorbonne University in Paris. He's also an internationally recognized researcher in the field of inflammatory bowel disease, gut microbiota, fecal microbiota, transplantation, and not only has done really interesting work in some of these specific fields, as well as developing some potentially innovative treatments that we'll discuss, but has also been very clear to public talk about the excessive hype that can sometimes come in this field when headlines that we see are drawn beyond what the evidence can actually conclude, as well as when we base certain beliefs or conclusions in this area, on the types of evidence that can't really demonstrate those things, at least in a causal manner. We're going to try and discuss a variety of these issues as we go through this episode. For those of you who are premium members, of course, you will get a set of detailed study notes to accompany this episode, which you can click through in the description box or over on the website when you go to this specific episode. For those of you listening on the free public feed of the podcast, if you're interested in getting more out of this podcast learning, using this more as an educational resource that you can learn a bit deeper from, that you can revise over quicker, that you can pull information from, and then translate into your either own learning or your own content, etc. Then check out what we offer with a Sigma Nutrition premium subscription. All of that will be linked up in the description box where you're currently listening. And of course, you can also click through to the episode page there as well, and I'll give some more related resources to this particular episode. So with that out of the way, let's dive into this conversation between myself and Professor Harry Sokol.
Professor Harry Sokol, thank you so much for taking the time to come and join me on the podcast today.
Harry Sokol (2:54)
Thank you. Very happy to be with you today.
Danny Lennon (2:56)
The pleasure is all mine. I've been really intrigued to put a number of questions to you, because as we'll get to, this is an area that there's been a lot of interest generated, but I think still there's a bit of confusion, given how sometimes some of the claims might outpace some of the evidence. But before we get to any of that, maybe for people listening and to give them a bit of context, can you give them an introduction into your academic background, your research interests, the work you do, anything else that might be relevant for our discussion today?
Harry Sokol (3:29)
Sure. So I'm a gastroenterologist. I'm professor of medicine in Paris, in St. Antoine Hospital and Sorbonne University. I have clinical activity, seeing mostly patients with inflammatory bowel disease. I'm also coordinating the Center for Fecal Microbiota Transplantation in the Paris area.
I have a research lab focusing on host-microbiome interactions, really trying to understand these interactions between the host and the microbiome, with the idea to turn this science into medicine, either new drugs, new biomarkers, and this type of thing. And maybe something I want to disclose is that I co-funded the company, based on my research, to really develop one bacteria as a drug. And this is something currently in process with several clinical trials now ongoing.
Danny Lennon (4:22)
And we'll certainly get into that, and there's a few different areas that I want to touch on, and we'll come back to them at different time points. Because as you note, some of this work is really at the cutting edge of really interesting and intriguing research. But maybe to get a broader overview for people listening, because I'm sure they've heard a whole range of different claims when it comes to the microbiome, and then how things that we can do can interact with that.
Read the other 33 minutes of this episode here.
$15 gets you this episode and 99 more. Credits never expire. After checkout, one link brings you back here to read it.
Not what you expected? Full refund within 14 days.
Thousands of transcripts fetched by people building searchable podcast archives
Fetch transcripts with code
The same credits work from a script or an AI agent. The demo key returns a sample episode in full, no card needed:
curl -H "x-api-key: pt_demo" \
https://spoken.md/transcripts/1000651996090Markdown with the speakers named, for your notes, your knowledge base, or anything that makes HTTP calls.
From $0.10 per transcript. No subscription. Credits never expire. Prices exclude VAT, added at checkout for EU customers. Not what you expected? Email us within 14 days with 20 or fewer credits used and we refund the pack in full.
Using your own key:
curl -H "x-api-key: YOUR_KEY" \
https://spoken.md/transcripts/1000798306171